Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Inclusion Criteria:

• <24 months of age
• Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening

Exclusion Criteria:

• Chronic or congenital heart disease
• Required ventilation or admission to any pediatric Intensive Care Unit
• Inadequate organ function